TIDMREDX
Redx Pharma plc
06 November 2023
REDX PHARMA PLC
("Redx" or the "Company")
Redx Unveils Preclinical Data from New Development Candidate,
RXC009, a Novel, Selective Discoidin Domain Receptor 1
Inhibitor
Data from translational disease models supports development of
RXC009 as a potential first-in-class treatment for chronic kidney
disease
Alderley Park, UK, 6 November 2023 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease and cancer announces preclinical data
for RXC009, a recently nominated development candidate from its
Discoidin Domain Receptor (DDR) programme, was presented at the
American Society for Nephrology (ASN) Annual Meeting (2-5 November
2023, Philadelphia, US).
RXC009, a small molecule, orally available, highly potent and
selective DDR1 inhibitor, was nominated as a development candidate
in October 2023 and has potential to be a first-in-class treatment
option for chronic kidney disease (CKD) including kidney fibrosis
associated with CKD as seen in Alport Syndrome. DDRs have recently
gained traction as druggable targets with the potential to treat
multiple fibrotic conditions, however to date, no selective
inhibitors of DDR1 have entered the clinic.
RXC009 demonstrated excellent selectivity for DDR1 compared to
other disclosed DDR inhibitors when tested against kinase and other
target panels with limited off-target pharmacology. In a
therapeutic unilateral ureteral obstruction (UUO) murine model of
kidney fibrosis, RXC009 treatment resulted in a significant
reduction in histological markers of both inflammation and
fibrosis. Target engagement was also demonstrated in this model
with a 72% reduction in phospho-DDR1 (p-DDR1). RXC009 has a
favourable absorption, distribution, metabolism and excretion
(ADME) and safety profile with a Drug-Drug Interaction (DDI)
assessment completed confirming its suitability for potential use
in combination. These data further validate the hypothesis that
selective inhibition of DDR1 represents an attractive approach for
investigation towards the development of new treatments for CKD and
taken collectively, supports progressing RXC009 into IND-enabling
studies.
Richard Armer, Chief Scientific Officer, Redx Pharma, commented:
"This compelling preclinical data suggests that our selective DDR1
inhibitor, RXC009, has the potential to be a first-in-class
treatment with an initial indication in chronic kidney disease and
associated fibrosis, which remains a significant unmet medical
need. The nomination of our 10(th) development candidate again
highlights our medicinal chemistry expertise and unique ability to
develop novel drug candidates against historically challenging
disease targets."
As previously announced, the Company intends to partner its DDR
programme for further development as it focuses on advancing its
differentiated ROCK portfolio through clinical development.
About CKD and Alport Syndrome
CKD affects 8% to 16% of the population worldwide and is most
commonly attributed to diabetes and hypertension. Renal fibrosis,
characterised by tubulointerstitial fibrosis and
glomerulosclerosis, is one of the final manifestations of CKD as it
progresses and is associated with high morbidity(1) .
Alport Syndrome is an inherited disease that damages the tiny
blood vessels in the kidneys and can lead to kidney disease and
kidney failure. There is no specific approved treatment for Alport
Syndrome, with current standard of care aiming to treat the
symptoms and help slow the progression of kidney disease(2) . While
there are no reliable prevalence studies are available, Alport
Syndrome is estimated to affect less than 200,000 people in the
U.S.(3) , making it a rare disease.
For further information, please
contact:
Redx Pharma Plc T: +44 (0)1625 469
UK Headquarters 918
Caitlin Pearson, Head of Communications
ir@redxpharma.com
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330
Claes Spång/ Satheesh Nadarajah/ David
Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, targeted therapeutics for the treatment of fibrotic
disease, cancer and the emerging area of cancer-associated
fibrosis, aiming initially to progress them to clinical proof of
concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product
candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in
development for interstitial lung disease and is undergoing a Phase
2a trial for idiopathic pulmonary fibrosis (IPF) with topline data
expected in H1 2024. The Company's second fibrosis candidate,
RXC008, a GI-targeted ROCK inhibitor for the treatment of
fibrostenotic Crohn's disease, is progressing towards a CTA
application during the fourth quarter of 2023. Redx's lead oncology
product candidate, the Porcupine inhibitor RXC004, being developed
as a targeted treatment for Wnt-ligand dependent cancers, is
expected to report anti-PD-1 combination Phase 2 data during the
first half of 2024, following which Redx will seek a partner for
ongoing development. In October 2023, Redx nominated its next
development candidate, RXC009 a highly potent and selective DDR1
inhibitor for the treatment of chronic kidney disease and
associated fibrosis.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its wholly-owned clinical-stage product candidates and
discovery pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA
for adult patients with mantle cell lymphoma previously treated
with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine
inhibitor targeting fibrotic diseases including IPF, which
AstraZeneca is progressing in a Phase 1 clinical study. In
addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which
Jazz is now progressing through Phase 1 clinical studies, and an
early-stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/ .
1. Taken in part from Chen TK et al; JAMA. 2019 Oct 1; 322(13):
1294Ð1304.
2. https://www.kidney.org/atoz/content/alport
3. https://alportsyndrome.org/about-alport-syndrome/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABLBDBLDGDGXX
(END) Dow Jones Newswires
November 06, 2023 02:00 ET (07:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Dec 2023 to Dec 2024
